RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Harbour Antibodies, the Dutch drug discovery subsidiary of Harbour BioMed, partnered with Boston’s Abveris to offer its fully-human antibody discovery services together with Abveris’ therapeutic antibody discovery services. Under a Co-Offering Agreement, Averis will be able to offer clients a low-upfront evaluation fee and pre-negotiated commercial terms. This will allow Abveris clients to consider the Harbour’s H2L2 human transgenic mouse technology before committing to a commercial license. Headquartered in Boston, Harbour Bio has operations in Shanghai and Suzhou.
Source: China Biotoday
